Neurotech International

Neurotech International Liabilities

The The Liabilities of Neurotech International (NTI.AX) as of Oct 27, 2026 is 2.14 M AUD. In the previous year, The Liabilities was 285,742.00 AUD — a change of 647.62% (higher).

Liabilities

2.14 MAUD

YoY

647.62%

Last updated:

In 2026, Neurotech International's total liabilities amounted to 2.14 M AUD, a 647.62% difference from the 285,742.00 AUD total liabilities in the previous year.

The Neurotech International Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2019
355,335.00 AUD
Jan 1, 2020
727,098.00 AUD
Jan 1, 2021
1.14 M AUD
Jan 1, 2022
592,980.00 AUD
Jan 1, 2023
1.35 M AUD
Jan 1, 2024
314,699.00 AUD
Jan 1, 2025
285,742.00 AUD
Jan 1, 2026
2.14 M AUD
The Neurotech International Liabilities history
YEARLiabilitiesYoY
2.14 MAUD+647.62%
285,742.00AUD-9.20%
314,699.00AUD-76.63%
1.35 MAUD+127.14%
592,980.00AUD-48.19%
1.14 MAUD+57.40%
727,098.00AUD+104.62%
355,335.00AUD-5.41%
375,660.00AUD-42.83%
657,038.00AUD-26.43%
893,122.00AUD-55.08%
1.99 MAUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neurotech International Stock analysis

What does Neurotech International do? Neurotech International Ltd. generates revenue through the development and commercialization of medical devices and solutions, primarily targeting pediatric neurological disorders. The company's key product, Mente Autism, is a portable EEG headband that uses closed-loop neurofeedback to assist children with autism spectrum disorder (ASD) by improving relaxation and engagement. Clinical studies assess the neuro-protective and anti-inflammatory effects of its NTI/Dolce cannabis strains, which are part of its development program NTI164 that completed a Phase I/II trial for ASD treatment. The firm focuses on commercializing these neurological solutions for pediatric use in home therapy settings. The company's primary customers are families and healthcare providers managing children with autism spectrum disorder (ASD). Mente Autism is marketed as a home therapy device to increase engagement and reduce anxiety in autistic children with elevated delta-band brain activity. Neurotech International Ltd. leverages its clinical trial results to support the commercialization of Mente Autism and its NTI/Dolce cannabis strains, which are positioned as therapeutic solutions for neurological conditions. The firm's revenue streams are derived from the sale of Mente Autism devices and the potential future commercialization of its NTI/Dolce cannabis-based products. Neurotech International Ltd. operates within the medical device sector, emphasizing pediatric neurological solutions. Its products, including Mente Autism and the NTI/Dolce cannabis strains, are developed through clinical studies to address specific neurological disorders. The company's focus on home-based therapy for ASD patients differentiates its offerings in the market, targeting a niche segment of families seeking non-invasive, accessible treatments for children with autism. Neurotech International is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Neurotech International's Liabilities

Neurotech International's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Neurotech International's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Neurotech International's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Neurotech International's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Neurotech International’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Neurotech International stock

The Liabilities of Neurotech International is 2.14 M AUD in 2026.

The Liabilities of Neurotech International changed from 285,742.00 AUD to 2.14 M AUD, representing a 647.62% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Neurotech International since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Neurotech International historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Neurotech International

All Key Metrics — Neurotech International